Landmark FDA clearance of whole exome sequencing in vitro diagnostic (IVD) test reporting overall tumor mutation burden (TMB) by sequencing...
Q3 Financial Highlights: Total revenue was $22.4 million SaaS revenue was $18.3 million, up 15% from Q3 2018 Total gross...
Culver City, Calif. – October 30, 2019 — NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced...
Attendees to Learn about Product Upgrades, Share Experiences and Network with Colleagues Mountain View, CA – October 25, 2019 –...
Leading Health IT Organizations Exclusively Selected to Participate in the HIMSS Interoperability Showcase™ Bangkok, Thailand & Culver City, CA –...
Leading Provider of Connected Care Solutions Continues to Innovate at the Patient Bedside Chicago, IL & Culver City, CA –...
This designation reaffirms that NantHealth is a trusted leader in utilization review and is committed to quality and transformative healthcare,...
Q2 Financial Highlights: Fourth consecutive quarter of total revenue growth Total revenue was $25.7 million, up 17% from Q2 2018...
Culver City, Calif. – August 1, 2019 — NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced...
NantHealth to Showcase Advancements in Technology that Enable Value-Based Care and Discuss Technology’s Role in Reducing Healthcare Costs Culver City,...
Culver City, CA – June 13, 2019 – NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced its...
Members of the NantHealth Connected Care Team to Highlight the Importance of Interoperability in Today’s Global Healthcare Ecosystem Helsinki, Finland...